NVO - Obesity Medication Insurance Coverage? Employers Embrace the Inclusion of Novo Nordisk's Wegovy in Health Coverage | Benzinga
Coverage for obesity medications, including Novo Nordisk A/S's (NYSE: NVO) Wegovy, is expected to expand among U.S. employers, according to a new survey conducted by healthcare program provider Accolade Inc (NASDAQ: ACCD) and research firm Savanta.
The survey indicates a growing willingness among employers to include GLP-1 drugs like Wegovy in their health coverage plans amid rising healthcare costs associated with the increased popularity of such weight-loss treatments.
Accolade and Savanta polled 502 employers, Reuters ...